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Immune modulating therapy, such as tumour necrosis factor (TNF)-alpha inhibitors, is becoming
increasingly more widespread in the treatment of many autoimmune diseases. One of the well-
documented side effects of TNF-alpha inhibitors is an increased risk of reactivating latent tuberculosis
infection (LTBI). Diagnostic tools available for diagnosing LTBI lack sensitivity and speciﬁcity. We report
the case of a rheumatoid arthritis (RA) patient at high-risk of reactivation of LTBI, who should have been
offered prophylactic anti-tuberculous treatment on two separate occasions: ﬁrstly, before initiating anti-
TNF-a treatment and secondly, as part of routine tuberculosis contact tracing. He subsequently devel-
oped severe pulmonary tuberculosis and was hospitalised for 6 weeks.
 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Biological drugs, including TNF-a inhibitors, play a crucial role
in the treatment of many dermatologic, gastro-intestinal and
rheumatologic autoimmune diseases e especially RA. It is well
known that these drugs increase the risk of serious infections, in
particular reactivation of LTBI as well as malignancies.1,2 The esti-
mated incidence of LTBI in Danish patients undergoing anti-TNF-
a treatment is 25/100,000 per year3; this equals a four-fold
increase compared to the background incidence of 6/100,000 per
year4 In Denmark, following international guidelines,5 all patients
are screened for LTBI before the initiation of immunomodulating
drug therapy.
The traditional method for detecting LTBI, the tuberculin skin
test (TST), has a lower sensitivity in patients receiving corticoste-
roids,6 and the speciﬁcity is dependant of the bacilli Calmette-
Guerin (BCG) vaccination status of the patient.
The Mycobacterium tuberculosis-speciﬁc interferon-g release
assays (IGRA) have proven superior to the TST in having a higher
speciﬁcity in BCG vaccinated patients and a slightly higher sensi-
tivity generally e even in immune compromised hosts there are
generally more responses to IGRA compared to TST.7 Despite its
higher sensitivity, there is still a risk of false negative or inconclu-
sive test results, especially in patients undergoing45 35456648.
(A.-S.H. Christensen).
-NC-ND license.immunosuppressive treatment. Recent studies have shown that
corticosteroid treatment on its own lowers the sensitivity of IGRAs
signiﬁcantly8,9e this poses a challengewhen screening RA patients
before initiating TNF-a treatment, because almost all these patients
are already being treatedwith corticosteroids, such as prednisolone
(PSL).
This case report aims to illustrate the importance of conducting
a full risk-assessment in the pre-anti-TNF-a-therapy screening and
not relying on a negative or inconclusive IGRA result to rule out
LTBI. A thorough evaluation of risk factors such as ethnicity, age,
current medications and recent exposure to TB is essential. This
informationmust then be further assessed along with the results of
currently available diagnostic tools for LTBI e the TST (in non-BCG
vaccinated patients) and IGRA e and ﬁnally, chest X-ray.2. Case report
A 45-year old male of Greenlandic origin was admitted to the
acute medical ward at a university hospital in Copenhagen in May
2010 with a productive cough, weight loss and general malaise of
one-week duration. He had a medical history of severe sero-
negative RA and Bechterew’s disease, and was being treated with
PSL 5 mg daily, Methotrexate (MTX) 12.5 mg weekly and Inﬂiximab
(INF) infusions every 8 weeks.
The patient was born and raised in Greenland, had moved to
Denmark 13 years ago, and socialised within the Greenlandic
community in Copenhagen. The patient had previously been
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substance abuse.
Vital parameters upon admission showed a normal blood
pressure (119/80), a respiratory rate of 14, tachycardia (pulse 90)
and subfebrility (temp. 37.7 C). Clinical examination revealed
pallor and cold sweating. Chest examination revealed a dampened
percussion over the basal right lung ﬁeld with reduced breath
sounds upon auscultation. Abdominal examination found epigas-
tric tenderness.
Routine laboratory investigations revealed elevated leucocytes
10.3 (reference: 3.0e9.0), thrombocytosis of 522 (reference:
140e340), sodium 130 (reference: 136e146) and CRP 241 (refer-
ence: <10). Chest X-ray found a right-sided basal inﬁltrate and
pleural effusion (see Fig. 1A and B).
A tentative diagnosis of bacterial pneumonia was made and
intravenous Cefuroxime treatment was initiated. Sputum and blood
cultures were later found negative for bacteria and fungi. Direct
microscopy of sputum and pleural ﬂuid were both found negative
for Mycobacterium tuberculosis complex.
In the following days the patient’s clinical condition deterio-
rated with tachypnoea (respiratory rate 35e40), rising body
temperature (39e40 C) and sinus-tachycardia (rate 100e120).
Medication was altered to intravenous Meropenem.
One-week later, another sputum test was analysed for
M. tuberculosis; this was also microscopy negative, but was found
positive using nucleic acid ampliﬁcation (NAA) testing. A gastric
lavage ﬂuid sample was at the same time also found positive both
through direct microscopy and NAA testing. Anti-tuberculous
treatment was started immediately. The sputum sample revealed
growth of fully sensitiveM. tuberculosis after several weeks’ culture.
The patient recovered slowly andwas discharged after three weeks.
Two days later, the patient was re-hospitalised in a weakened,
febrile state and with radiological progression of residual pleural
effusion; he was discharged after three weeks.
Prior to initiating INF treatment in September 2009, the
outpatient rheumatology clinic that followed the patient had tested
him for LTBI using TST, chest X-ray and QFT. The TST was negative
and the chest X-ray showed, according to the radiologist, apical
unilateral chronic calciﬁcations; the x-ray is in the patient ﬁle
described as ‘normal’. QFT was inconclusive and the departmentFig. 1. 1A and 1B. Chest X-ray (frontal and lateral view) taken at time of primhad not followed the recommendation of repeating the test. It had
not been noted in the medical record whether or not the patient
was BCG vaccinated e in later entries from the infectious disease
departments, it is however noted that the patient had a BCG scar.
Throughout the course of the ﬁrst week of admission, it was
discovered that inMarch 2010, the patient had been tested for TB as
a routine part of contact tracing, due to recent contact with a newly
diagnosed pulmonary TB index patient. A chest X-ray at the time
revealed chronic pulmonary changes and the Quantiferon Gold in
tube (QFT) test was negative. The department in charge of contact
tracing claims not to have any knowledge of neither the patient’s
rheumatologic disease nor current medication. At the time of
testing, the patient was taking three different types of immuno-
suppressive treatment: PSL, MTX, INF.
The patient has now completed the follow-up program at an
infectious disease outpatient clinic and has received a total of 9
months of anti-tuberculous treatment; the reason for choosing
a longer regime was partly that INF infusions were continued
during the anti-tuberculous treatment and partly due to compli-
ance issues.
3. Discussion
The above case illustrates a patient who, in two separate
instances, should have been offered prophylactic anti-tuberculous
chemotherapy: ﬁrstly, prior to starting INF treatment and
secondly, through contact tracing.
At time of LTBI screening prior to INF treatment, the patient was
already receiving two types of immunosuppressive medication e
PSL and MTX. It has been shown, that PSL treatment lovers the
sensitivity of IGRAs and must therefore be interpreted with care; in
this case, the QFT was inconclusive and should have been repeated.
The TST is ultimately useless, since the patient was BCG vaccinated.
At this point the patient had a total of three risk factors relating to
an increased risk of LTBI: ﬁrstly, the patient was born and raised in
Greenland, a country of high TB-endemicity; in 2009, an incidence
of 112/100,000 was reported,10 and this must be viewed in
comparison with the signiﬁcantly lower TB incidence in Denmark
of 6/100,000.4 Secondly, he was undergoing immunosuppressive
treatment; thirdly the chest x-ray showed apical calciﬁcations thatary admission showing right-sided basal inﬁltrate and pleural effusion.
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combined should, in the authors’ opinions, have resulted in
prophylactic anti-tuberculous chemotherapy. According to Danish
recommendations, the patient would have been eligible for
prophylaxis just by being an immigrant from a country of high
tuberculosis endemicity (incidence over 50/100,000).3
At the time of contact tracing, the patient had added yet another
two risk factors to the ones mentioned above: he had initiated INF
treatment and he had been in close contact with a recently diag-
nosed and contagious pulmonary TB index patient. A thorough
interview with the patient would have revealed these important
risk factors and would have resulted in prophylactic anti-
tuberculous chemotherapy e regardless of the negative QFT result.
In conclusion, the above case could have been prevented
through a systematic risk-assessment performed by the clinicians
at both departments involved. None of the diagnostic tools avail-
able for diagnosing LTBI are 100% sensitive and must therefore be
used in conjunction with an overall risk stratiﬁcation. QFT test
results must be interpreted with caution in a patient who is in an
immunosuppressive state. It could be suggested that certain high-
risk individuals, such as this Greenlandic RA patient, should be
tested for LTBI and/or active TB before initiating any form of
immune modulating therapy, even PSL.
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